Arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine
Arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine has been studied in 1 paper since 2026: none in people yet, 1 in cells; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 31, 2026: “In vitro effects of synthetic immunotropic hexapeptides on CD63-CD16+CD62L+CD11b+ and CD63+CD16+CD62L+CD11b+ neutrophilic granulocytes in elderly and senile patients with chronic obstructive…”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine
At a glance
The findings reach cells, none yet in people. 1 lab in 1 country.
- 1 lab in 1 country
- Cells1
What did studies of arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine find?
1Studies of arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine measured one outcome, CD63+ neutrophil subsets.
CD63+ neutrophil subsets
downin human cells1
1 study
CD63+ neutrophil subsets
downin human cells1
Arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine decreases CD63+ neutrophil subsets in human cells (chronic obstructive pulmonary disease).
“After incubation with arginyl-a-aspartyl-lysyl-valyl-tyrosyl-arginine, an increase in the neutrophil granulocyte subset CD63-CD16brightCD62LbrightCD11bbright was observed, while the CD63+CD16brightCD62LbrightCD11bbright and CD63+CD16brightCD62LdimCD11bbright neutrophil subsets were reduced.”
Cellschronic obstructive pulmonary diseaseperipheral blood neutrophilic granulocytes
Russian Journal of Immunology